Highbridge Capital Management LLC Raises Stake in Seres Therapeutics, Inc. (MCRB)
Highbridge Capital Management LLC raised its stake in shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) by 104.0% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 30,843 shares of the biotechnology company’s stock after buying an additional 15,726 shares during the period. Highbridge Capital Management LLC owned approximately 0.08% of Seres Therapeutics worth $347,000 as of its most recent SEC filing.
Other large investors have also bought and sold shares of the company. Renaissance Technologies LLC boosted its position in shares of Seres Therapeutics by 35.0% in the fourth quarter. Renaissance Technologies LLC now owns 400,300 shares of the biotechnology company’s stock valued at $3,963,000 after buying an additional 103,800 shares during the period. Vanguard Group Inc. raised its position in Seres Therapeutics by 7.1% in the first quarter. Vanguard Group Inc. now owns 1,565,663 shares of the biotechnology company’s stock valued at $17,645,000 after buying an additional 103,456 shares in the last quarter. Spark Investment Management LLC bought a new position in Seres Therapeutics during the first quarter valued at about $613,000. JPMorgan Chase & Co. raised its position in Seres Therapeutics by 15.9% in the first quarter. JPMorgan Chase & Co. now owns 370,225 shares of the biotechnology company’s stock valued at $4,172,000 after buying an additional 50,860 shares in the last quarter. Finally, American Century Companies Inc. bought a new position in Seres Therapeutics during the first quarter valued at about $447,000. 75.52% of the stock is owned by institutional investors.
Seres Therapeutics, Inc. (NASDAQ:MCRB) traded down 3.08% during trading on Thursday, hitting $12.91. The stock had a trading volume of 242,038 shares. The firm’s market capitalization is $521.45 million. The stock has a 50 day moving average of $11.94 and a 200 day moving average of $10.51. Seres Therapeutics, Inc. has a one year low of $8.85 and a one year high of $15.09.
Seres Therapeutics (NASDAQ:MCRB) last posted its quarterly earnings data on Thursday, August 3rd. The biotechnology company reported ($0.69) earnings per share for the quarter, missing the consensus estimate of ($0.64) by $0.05. The company had revenue of $3 million during the quarter, compared to analyst estimates of $3 million. Seres Therapeutics had a negative return on equity of 68.86% and a negative net margin of 441.10%. The business’s revenue for the quarter was up .0% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.70) EPS. Equities research analysts expect that Seres Therapeutics, Inc. will post ($2.65) earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: This news story was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/08/03/seres-therapeutics-inc-mcrb-shares-bought-by-highbridge-capital-management-llc-updated-updated-updated.html.
Several research firms have issued reports on MCRB. BidaskClub upgraded Seres Therapeutics from a “hold” rating to a “buy” rating in a research note on Tuesday, July 25th. ValuEngine upgraded Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday. Canaccord Genuity set a $20.00 target price on Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday. Zacks Investment Research upgraded Seres Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 target price for the company in a research note on Wednesday, July 5th. Finally, Cantor Fitzgerald set a $16.00 target price on Seres Therapeutics and gave the company a “buy” rating in a research note on Thursday, May 4th. One research analyst has rated the stock with a hold rating and seven have assigned a buy rating to the stock. Seres Therapeutics presently has a consensus rating of “Buy” and an average price target of $15.60.
About Seres Therapeutics
Seres Therapeutics, Inc is a microbiome therapeutics platform company. The Company is engaged in developing a class of biological drugs, which is referred as Ecobiotic microbiome therapeutics. The Company’s drugs are designed to restore health by repairing the function of a dysbiotic microbiome. The Company is focused on implementing its microbiome therapeutics platform to develop Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome.
Receive News & Stock Ratings for Seres Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics Inc. and related stocks with our FREE daily email newsletter.